

A close-up photograph of a cannabis plant with green leaves and a large, developing bud. The image is overlaid with a dark blue gradient.

ORGANIGRAM
GLOBAL

Investor Presentation

March 31, 2026

ORGANIGRAM
GLOBAL

CAUTIONARY STATEMENT

This document is current as of March 31, 2026, except where otherwise stated. The information contained in this presentation is provided by Organigram Global Inc. ("Organigram" or the "Company") for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Organigram or other financial products. No part of this presentation shall form the basis or be relied upon in connection with any contract, commitment or investment decisions in relation thereto. The information contained herein is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. No securities commission or similar regulatory authority in Canada or the United States has reviewed this presentation. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. This presentation is not meant to provide a complete or comprehensive analysis of Organigram's financial or business prospects. To the maximum extent permitted by law, none of Organigram nor its directors, officers, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of the information contained in this presentation.

This presentation contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "estimates", "intends", "anticipates", "believes" or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, including but not limited to the expectations regarding the expected additional net revenue and international sales volume as a result of the acquisition of Sanity Group GmbH ("Sanity Group"). Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this presentation. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and risks as disclosed in the Company's most recent annual information form, management's discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation.

Certain forward-looking information included herein may also constitute a

"financial outlook" within the meaning of applicable securities legislation. Financial outlook involves statements about the Company's prospective financial performance and financial position that are based on and subject to the assumptions about future economic conditions and courses of action described above as well as management's expectations regarding a strong innovation pipeline, increasing international sales, high cannabis quality and higher potency, commercialization of FAST nano-emulsion technology in ingestible formats, and receipt of the EU-GMP certification. Such assumptions are based on management's assessment of the relevant information currently available and any financial outlook included herein is provided for the purpose of helping readers understand management's current expectations and plans for the future as of the date hereof. The actual results of the Company's operations may vary from the amounts set forth in any financial outlook and such variances may be material. Readers are cautioned that reliance on any financial outlook may not be appropriate for other purposes, or in other circumstances and that the risk factors described above and other factors may cause actual results to differ materially from any financial outlook.

Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this presentation are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this presentation is made as of the date of this presentation and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The descriptions of the terms of the agreements referenced in this presentation are qualified by the terms of the agreements themselves, copies of which shall be filed under Organigram's profile on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov).

The financial information in this document contains certain financial performance measures that are not defined by and do not have any standardized meaning under International Financial Reporting Standards ("IFRS") and are used by management to assess the financial and operational performance of the Company. These include adjusted EBITDA and adjusted gross margin (adjusted gross margin %). The Company believes that these non-IFRS financial measures, in addition to conventional measures prepared in accordance with IFRS, enable investors to evaluate the Company's operating results, underlying performance and prospects in a similar manner to the Company's management. As there are no standardized methods of calculating these non-IFRS measures, the Company's approach may differ from those used by other issuers, and accordingly, the use of these measures may not be directly

comparable. The most directly comparable measure to adjusted EBITDA calculated in accordance with IFRS is net income (loss). The most directly comparable measure to adjusted gross margin calculated in accordance with IFRS is gross margin before fair value adjustments. Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. For further information regarding these non-IFRS measures, including definitions, and a quantitative reconciliation to the most directly comparable IFRS measure, see the information under the heading "Cautionary Statement Regarding Certain Non-IFRS Measures" and the reconciliation to IFRS measures under the heading "Financial Results and Review of Operations" in the Company's management discussion and analysis of financial conditions and results of operations for the three and six months ended March 31, 2026 (the "Q2 Fiscal 2026 MD&A") incorporated by reference in this presentation and filed under Organigram's profile of SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). This presentation does not constitute an offer of shares for sale in the United States or to any person that is, or is acting for the account or benefit of, any U.S. person as defined in Regulation S under the United States Securities Act of 1933, as amended (the "Securities Act"), or in any other jurisdiction in which such an offer would be illegal. Organigram's shares have not been and will not be registered under the Securities Act. We seek safe harbour. This document may not be reproduced, further distributed or published in whole or in part by any other person. This document may only be disseminated or transmitted into any jurisdiction in compliance with, and subject to, applicable securities laws. Readers are required to ensure their compliance with applicable securities laws.

This investor presentation contains information concerning our industry and the markets in which we operate, including our market position and market share, which is based on information from independent third-party sources. Although we believe these sources to be generally reliable, market and industry data is inherently imprecise, subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process, and other limitations and uncertainties inherent in any statistical survey or data collection process. We have not independently verified any third-party information contained herein.

All dollar values are in Canadian dollars unless otherwise indicated.

Figures in this presentation are approximate due to rounding.

Canadian Roots. Naturally Global.



13 YEARS OF RESPONSIBLE LEADERSHIP

Founded in 2013, Organigram transitioned from a leading medical cannabis company to the #1 recreational LP by market share in Canada¹



WORLD CLASS CAPABILITIES

Organigram operates five advanced cultivation, production, manufacturing, and logistics facilities across Canada



INNOVATION TRAILBLAZER

Organigram is a leader in creating innovative, differentiated products, and honing its production practices



GLOBAL STRATEGY

In April 2026, Organigram acquired one of Germany's top medical cannabis companies, Sanity Group, becoming a leader in the world's two largest federally legal markets of Canada and Germany



RAPID INTERNATIONAL EXPANSION

Organigram exports international medical flower to multiple jurisdiction and has launched branded sales for derivative products in the U.S. and Australia

1. Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of March 2026.



Canada's #1 LP in market share¹

RECREATIONAL MARKET



VAPES

#1



CONCENTRATES

#1



MILLED FLOWER

#1



PRE-ROLLS
(including IPRs)

#2



FLOWER
(including milled)

#2



EDIBLES

#3

1. Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of March, 2026.

State-of-the-art Facilities

Canada's largest indoor cultivation



Winnipeg, MB

- Edibles facility with automated cutting-edge equipment
- Ramping up beverage production capabilities



Aylmer, ON

- Advanced capabilities & centralized manufacturing:
- Hydrocarbon extraction
 - Refining, formulation, post-processing of minor cannabinoids
 - Infused and regular pre-rolls



London, ON

- Centralized distribution hub to support growing demand and to optimize fulfillment



Lac-Supérieur, QC

- Producing hang-dried, hand-trimmed, artisanal cannabis
- Producing multiple hash products, including the patent-pending Rip-Strip Hash



Moncton, NB

- Three-tiered, modular, strain-specific grow rooms provide the ability to control critical environmental requirements by strain
- In-house cannabinoid testing, and remediation
- EU-GMP certification in progress

Moncton Spotlight: Canada's Largest Indoor Facility



500,000 square-foot facility with 144 modular and climate-controlled rooms and cultivation capacity of well over 100,000 kg annually



Each cultivation room grows vertically on three tiers, maximizing canopy space and minimizing cultivation costs per square foot



In-house R&D labs advancing genetic screening & selection for disease and mold resistance and desired plant characteristics




Implementing automation across production verticals as well as conducting in-house testing and remediation to leverage scale while ensuring quality and consistency

Coast to Coast Canadian Leadership by Market Share




Fiscal YTD Highlights


In millions unless otherwise indicated



Net Revenue



International Sales



Adjusted Gross Margin¹

Closed acquisition of Sanity Group. Sanity Group is projected to achieve an average of €25 million per quarter in net revenue over the next calendar year


Expanded branded international sales with the launch of 10 vape and edibles SKUs under the BOXHOT and EDISON brands in Australia. Branded beverage and edibles products also available in the U.S.²

Expanded cultivation capacity and efficiency with continued sequential improvement to plant yields and potency through enhanced cultivation techniques, seed-based cultivation, and achievements in plant sciences

1. Adjusted EBITDA is a non-IFRS financial measure not defined by and does not have any standardized meanings under IFRS, as issued by the International Accounting Standards Board, and might not be comparable to similar financial measures disclosed by other issuers; please refer to cautionary statement at the beginning of this document and the Company's Q2 Fiscal 2026 MD&A for definitions and a reconciliation to IFRS.
2. November 2025, the U.S. enacted the Continuing Appropriations and Extensions Act of 2026 (H.R. 5371), which includes a provision (section 781) to amend the definition of hemp in the 2018 Farm Bill to effectively eliminate hemp-derived THC products, although the change does not become effective for 365 days from the date of enactment. Organigram's U.S. offerings would be directly impacted by this change in law; additionally, Organigram has investments in hemp seed and hemp ingredient manufacturers in the U.S. that would also likely be negatively impacted by this legislation. Efforts are underway to repeal, replace, or delay this amendment, but whether any change will occur is uncertain. If current federal legislation is not amended or reversed, Organigram may have to sell or wind-down its hemp THC product related activities in the U.S. by November 2026.

Sanity Group Acquisition¹

Organigram completed its acquisition of one of Germany's cannabis leaders, Sanity Group, in April 2026 to become the only pure-play cannabis company with leadership positions in the world's two largest federally legal markets, Canada and Germany.



- ✓ **Organigram is #1 in Adult-Use Rec** in Canada's legal cannabis market² (>C\$6B annually), with Adult-Use representing 93% of total sales
- ✓ **C\$259.2M F'25 net revenue**, with analyst consensus >C\$340M in F'26
- ✓ **>100,000 kg/year indoor cultivation capacity**, supplying Canada and international medical markets (Germany, UK, Australia); Sanity is Organigram's #1 export customer
- ✓ **Branded international sales** in the U.S. (beverages, gummies) and Australia (vapes, gummies)
- ✓ **Three top-ten Canadian brands:** SHRED, BoxHot, Big Bag o' Buds

- ✓ **Sanity is a leading German cannabis company**, with active operations in Germany, Poland, the UK, Czechia, and Switzerland with expansion planned across additional European markets
- ✓ **Sanity becomes Organigram's European hub**, supporting future regional growth
- ✓ **Two Swiss pilot retail locations** with plans to expand European pilot participation in the future
- ✓ **Sanity revenue run rate expected to average €25 million per quarter** and expected to increase consolidated profitability and international sales volumes

1. This slide contains forward-looking information, please refer to the cautionary statement at the beginning of this presentation for more information on forward-looking information.
2. Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of March 31, 2026.

Expanding International Distribution



Germany

- Through its acquisition of Sanity Group, Organigram supplies medical flower to **Germany, the UK, Czechia, Poland**, and operates two **recreational Swiss pilot projects** with expansion plans underway



Australia

- Exporting medical whole flower to multiple customers
- Launched branded vape and edibles sales in Q2 Fiscal 2026



United Kingdom

- Exporting medical whole flower to multiple customers independent of Sanity Group



United States

- Producing and distributing Fetch and Collective Project beverages, and happy gummies available in over 20 States¹
- Strategic investments in Phyllos Bioscience Inc. ("Phyllos") and Steady State LLC (d/b/a Open Book Extracts)("OBX")

1. November 2025, the U.S. enacted the Continuing Appropriations and Extensions Act of 2026 (H.R. 5371), which includes a provision (section 781) to amend the definition of hemp in the 2018 Farm Bill to effectively eliminate hemp-derived THC products, although the change does not become effective for 365 days from the date of enactment (i.e. November 12, 2026). Non-compliant products will be classified as "marijuana" under the Controlled Substances Act as of the effective date. Organigram's U.S. offerings would be directly impacted by this change in law; additionally, Organigram has investments in hemp seed and hemp ingredient manufacturers in the U.S. that would also likely be negatively impacted by this legislation. Efforts are underway to repeal, replace, or delay this amendment, but whether any change will occur is uncertain. If current federal legislation is not amended or reversed, Organigram may have to sell or wind-down its hemp THC product related activities in the U.S. by November 2026.

Portfolio of Brands

Delivering strong coverage across all segments and categories — now expanding into Europe with the Sanity portfolio.

PREMIUM 6 BRANDS

DEBUNK

Canada, U.S.A.

Flower, Pre-Rolls, Infused Pre-Rolls, Vapes

COLLECTIVE PROJECT

Canada, U.S.A.

Beverages

Trailblazer

Canada

Pre-Rolls, Infused Pre-Rolls, Vapes

TREMBLANT

Canada

Pre-Rolls, Hash

happly

U.S.A.

Beverages

grashaus projects

New, Switzerland

REC, Vapes, Beverages, Edibles, Ointment

MAINSTREAM 7 BRANDS

BOX HOT

Canada, Australia

Flower, Pre-Rolls, Infused Pre-Rolls, Vapes

monjour

Canada

Beverages

EDISON CANNABIS CO

Canada, Australia

Edibles, Ointment

Feet

Canada, U.S.A.

Beverages

Vayamed

New, Germany / EU

MED, Hash, Concentrates

vaay

New, Germany / EU

REC CBD, Ointment, Vapes

avaay

New, Germany / EU

MED, Hash, Concentrates

VALUE 6 BRANDS

SHRED

Canada

Flower, Pre-Rolls, Infused Pre-Rolls, Vapes, Beverages

BIG BAGO BUDS

Canada

Pre-Rolls, Hash

PIZZIERS

Canada

Pre-Rolls, Vapes

WOLAH!

Canada

Pre-Rolls, Hash

ZOIKS

New, Germany / EU

MED, Hash

tannenbusch

New, Germany / EU

MED, Hash

Flower Milled Pre-Rolls Infused Pre-Rolls Vapes Beverages Edibles Hash Concentrates Oils Ointment

Canada U.S.A. Australia Germany / EU Switzerland

SHRED

- Award-winning mainstream brand
- Now leveraging FAST nanoemulsion technology for ingestible products



BOXHOT

- #1 concentrates and #2 Canadian vape brand by market share¹
- Portfolio includes IPRs, and other 2.0 products



BIG BAGO' BUDS

- #2 flower brand in Canada¹
- Focused on larger formats catering to quality-conscious value consumers



1. Multiple Sources (Hifyre, Weedcrawler, provincial boards, internal modelling) as of March, 2026.

COLLECTIVE PROJECT ★

- Award winning sparkling juices and lemonades
- Supports the arts community



Fetch

- Value-priced soda brand with top selling flavours like cola, lemon-lime and cream soda
- 1% of profits support local animal charities



happly

- Gummy brand offering low THC + functional ingredients like caffeine, chamomile extract and l-theanine to target specific mood states like socialize, relax and sleep



1. November 2025, the U.S. enacted the Continuing Appropriations and Extensions Act of 2026 (H.R. 5371), which includes a provision (section 781) to amend the definition of hemp in the 2018 Farm Bill to effectively eliminate hemp-derived THC products, although the change does not become effective for 365 days from the date of enactment (i.e. November 12, 2026). Non-compliant products will be classified as "marijuana" under the Controlled Substances Act as of the effective date. Organigram's U.S. offerings would be directly impacted by this change in law; additionally, Organigram has investments in hemp seed and hemp ingredient manufacturers in the U.S. that would also likely be negatively impacted by this legislation. Efforts are underway to repeal, replace, or delay this amendment, but whether any change will occur is uncertain. If current federal legislation is not amended or reversed, Organigram may have to sell or wind-down its hemp THC product related activities in the U.S. by November 2026.

Strategic Partnership with BAT:

2021

\$221 Million

- Established the PDC with formation of a Center of Excellence at Moncton campus
- Focused on developing the **next generation of cannabis products**, IP and technologies

2024

\$125 Million

- Creation of **strategic investment pool named Jupiter**, funded with \$83.1 million
- **\$41.5 million** proceeds for general corporate purposes

2026

\$65 Million

- Financing provided to support **acquisition of Sanity Group**, alongside final deployment of Jupiter Pool

U.S. Investments



Open Book Extracts

MANUFACTURING & FORMULATION

- **U.S.\$2 million** investment into **U.S.-based OBX**.¹
- A hemp-derived cannabinoid producer.
- Provides further footprint in the U.S.



SEED-BASED TECHNOLOGY

- **US\$10 million** investment into **U.S.-based Phylos** to access flower-derived minor cannabinoids such as THCV and initiate the conversion of a portion of Organigram's garden to more cost-effective seed-based production.
- Expected to deliver Organigram enhanced operational security, priority access to selected genetics, and a robust seed pipeline through 2030
- Moving toward catalogue of F1 stabilized seeds with consistent targeted traits.
- 25% of flower harvest at Moncton facility was seed-based in Q2 Fiscal 2026.

1. November 2025, the U.S. enacted the Continuing Appropriations and Extensions Act of 2026 (H.R. 5371), which includes a provision (section 781) to amend the definition of hemp in the 2018 Farm Bill to effectively eliminate hemp-derived THC products, although the change does not become effective for 365 days from the date of enactment (i.e. November 12, 2026). Non-compliant products will be classified as "marijuana" under the Controlled Substances Act as of the effective date. Organigram's U.S. offerings would be directly impacted by this change in law; additionally, Organigram has investments in hemp seed and hemp ingredient manufacturers in the U.S. that would also likely be negatively impacted by this legislation. Efforts are underway to repeal, replace, or delay this amendment, but whether any change will occur is uncertain. If current federal legislation is not amended or reversed, Organigram may have to sell or wind-down its hemp THC product related activities in the U.S. by November 2026.


Uniformity and Robustness of Seed Grow



Clones

Seeds


Q2 F'26 Revenue and Margins



1. Adjusted gross margin and adjusted gross margin %, are non-IFRS financial measures not defined by and do not have any standardized meanings under IFRS, as issued by the International Accounting Standards Board, and might not be comparable to similar financial measures disclosed by other issuers; please refer to cautionary statement at the beginning of this document and the Company's Q2 Fiscal 2026 MD&A for definitions and a reconciliation to IFRS.

Q2 F'26 International Sales

- International sales trajectory expected to be accelerated by integration of Sanity Group
- EU-GMP certification of Moncton in progress, expected to increase sales and margins



¹ In November 2025, the U.S. enacted the Continuing Appropriations and Extensions Act of 2026 (H.R. 5371), which includes a provision (section 781) to amend the definition of hemp in the 2018 Farm Bill to effectively eliminate hemp-derived THC products, although the change does not become effective for 365 days from the date of enactment. Organigram's U.S. offerings would be directly impacted by this change in law; additionally, Organigram has investments in hemp seed and hemp ingredient manufacturers in the U.S. that would also likely be negatively impacted by this legislation. Efforts are underway to repeal, replace, or delay this amendment, but whether any change will occur is uncertain. If current federal legislation is not amended or reversed, Organigram may have to sell or wind-down its hemp THC product related activities in the U.S. by November 2026.

Q2 F'26 Adjusted EBITDA¹



1. Adjusted EBITDA is a non-IFRS financial measure not defined by and does not have any standardized meanings under IFRS, as issued by the International Accounting Standards Board, and might not be comparable to similar financial measures disclosed by other issuers; please refer to cautionary statement at the beginning of this document and the Company's Q2 Fiscal 2026 MD&A for definitions and a reconciliation to IFRS.

Balance Sheet

Q2 Fiscal 2026:

\$54.8 million¹

Total cash

(including restricted cash
& short-term investments)

\$4.3 million

Unrestricted cash

Subsequent to Q2 F'26 Organigram:

\$60 million Loan Facility

- \$20 million non-revolving term facility used to partially fund Sanity Group acquisition
- \$30 million revolving credit facility
- \$10 million operating facility for general corporate purposes



Q2 FY26 Select Financial Metrics

In 000's unless otherwise indicated

Select Key Financial Metrics (in \$000s unless otherwise indicated)	Q2-2026	Q2-2025	% Change
Gross revenue	93,250	102,763	(9)%
Excise taxes	(33,456)	(37,163)	(10)%
Net revenue	59,794	65,600	(9)%
Cost of sales	44,800	45,813	(2)%
Gross margin before fair value changes to biological assets & inventories sold	14,994	19,787	(24)%
Realized fair value on inventories sold and other inventory charges	(21,834)	(14,192)	54%
Unrealized gain on changes in fair value of biological assets	23,247	12,823	81%
Gross margin	16,407	18,418	(11)%
Adjusted gross margin ¹	18,441	21,921	(16)%
Adjusted gross margin % ¹	31%	33%	(2)%
Selling (including marketing), general & administrative expenses	23,609	22,490	5%
Net (loss) income	(921)	42,456	nm
Adjusted EBITDA ¹	869	4,908	(82)%
Cash (used in) provided by operating activities before working capital changes	(9,996)	(1,607)	522%
Net cash provided by (used in) operating activities	(6,760)	(16,585)	(59)%

1. Adjusted gross margin, adjusted gross margin % and adjusted EBITDA are non-IFRS financial measures not defined by and do not have any standardized meaning under IFRS and might not be comparable to similar financial measures disclosed by other issuers; please refer to the cautionary statement at the beginning of this document and the Company's Q2 Fiscal 2026 MD&A for definitions and a reconciliation to IFRS.

Q2 FY26 Select Balance Sheet Metrics

In 000's unless otherwise indicated

Select Balance Sheet Metrics (in \$000s)	March 31, 2026	December 31, 2025	% Change
Cash & short-term investments (including restricted cash)	54,754	84,420	(35)%
Biological assets & inventories	135,158	123,954	9%
Other current assets	60,174	76,523	(21)%
Accounts payable & accrued liabilities	73,139	89,247	(18)%
Working capital	161,341	158,738	2%
Property, plant & equipment	120,838	122,977	(2)%
Total assets	521,312	562,211	(7)%
Total liabilities	149,500	213,081	(30)%
Shareholders' equity	371,812	349,130	6%

Capital Structure

In 000's unless otherwise indicated

Capital Structure	March 31, 2026	May 7, 2026
Common shares issued and outstanding	136,468	140,775
Preferred shares ¹	13,794	49,204
Options (Weighted Average Exercise Price: \$10.20)	2,130	2,802
Warrants (Exercise Price: \$3.65)	4,451	4,450
Top-up rights (Weighted Average Exercise Price: \$1.90)	18,726	6,128
Restricted share units	3,178	3,464
Performance share units	1,946	2,014
Total fully diluted shares	180,693	208,837

1. The preferred shares are eligible, under certain scenarios, to be converted into common shares equaling 14,994,047 consisting of the original preferred shares of 13,794,163 that convert into one common share and accretion amounts that accrue to the preferred shares at an annual rate of 7.5% per annum. Since the preferred shares were issued under the second and third tranches of the Follow-On BAT Investment, they have collectively accrued 1,199,884 of additional common share conversion value.